Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...

Additionally, Yellow Balloon Therapy offers support to adults recognizing the universal need for emotional well-being. At Yellow Balloon Therapy, we celebrate differences, empower the powerless ...

550 subjects were randomized 1:1 to either two cycles of the Allurion Balloon 1 or a control group that received moderate intensity lifestyle therapy. Subjects in the treatment group received ...

announced today its plan to conduct a clinical study on the combined use of the Allurion Balloon and GLP-1 agonists, aiming to improve long-term adherence and tolerability to GLP-1 therapy.

“The goal of our study would be to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can lose significant weight while increasing muscle ...

The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy. Previous ...

Although the Allurion Balloon is currently an investigational device in the United States, the company offers the Allurion Virtual Care Suite to healthcare providers separately to tailor weight-loss ...